(Q33653620)

28 July 2017

1 reference

title

Gene therapy for prostate cancer. New perspectives on an old problem (English)

1 reference

28 July 2017

0 references

1 reference

Palapattu GS

1

1 reference

28 July 2017

Naitoh J

series ordinal

2

1 reference

28 July 2017

Belldegrun AS

series ordinal

3

1 reference

28 July 2017

publication date

1 May 1999

1 reference

Urologic Clinics of North America

28 July 2017

published in

1 reference

28 July 2017

volume

26

1 reference

28 July 2017

issue

2

1 reference

28 July 2017

page(s)

353-63, ix

1 reference

A triploblast origin for Myxozoa?

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: a novel therapy in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Re: Transrectal ultrasound

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

The efficient expression of intravascularly delivered DNA in rat muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

The BRCA1 and BRCA2 breast cancer genes.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Persistence in muscle of an adenoviral vector that lacks all viral genes

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Converting cancer genes into killer genes

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Improved cationic lipid formulations for in vivo gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Recombinant adeno-associated virus for muscle directed gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

In VivoAdenovirus-Mediated Gene Transfer of theEscherichia coliCytosine Deaminase Gene to Human Colon Carcinoma-Derived Tumors Induces Chemosensitivity to 5-Fluorocytosine

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Transforming growth factor beta upregulates the integrin-mediated adhesion of human prostatic carcinoma cells to type I collagen

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Cancer Gene Therapy Using Plasmid DNA: Pharmacokinetic Study of DNA Following Injection in Mice

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Site-specific integration by adeno-associated virus: a basis for a potential gene therapy vector

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Molecular genetics of tumor suppressor genes in prostate carcinoma: the challenge and the promise ahead

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Tumour suppressor genes in prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Physicochemical and pharmacokinetic characteristics of plasmid DNA/cationic liposome complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Gene therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Vaccinia virus: a tool for research and vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

CaPCURE's fourth meeting: the cutting edge of current prostate cancer research

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Gene therapy--the future is here: a guide to the practicing urologist

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Preclinical Pharmacokinetics, Manufacturing, and Safety Studies Supporting a Multicenter Cancer Gene Therapy Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Identification of diphtheria toxin via screening as a potent cell cycle and p53-independent cytotoxin for human prostate cancer therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Gene therapy for cancer: what have we done and where are we going?

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Demonstration of a rational strategy for human prostate cancer gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Antisense c-myc retroviral vector suppresses established human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Expression of ras oncogene p21 in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Inhibition of gene expression by anti-sense oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

Systemic gene expression after intravenous DNA delivery into adult mice

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970075-6

7 January 2021

10.1016/S0094-0143(05)70075-6

Identifiers

DOI

1 reference

28 July 2017

1 reference